In 2019, Pfizer granted MPP a non-exclusive, royalty-free, worldwide licence allowing potential future MPP sublicensees to access Pfizer’s preclinical, phase I, and phase IIa clinical study data and results with the aim to further study, develop and make available this potentially important component of new TB regimens. The Gates Medical Research Institute became an MPP licensee for Sutezolid in late 2020. MPP welcomes this latest agreement to further develop new TB regimens.

Access PAN-TB Press Release